A Critical Appraisal of Off-Label Use and Repurposing of Statins for Non-Cardiovascular Indications: A Systematic Mini-Update and Regulatory Analysis.

J Clin Med · 2025 · PMC12347899 · PMID 40807057

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Clinically, patients on both agents showed a trend toward improved median overall survival (~15.5 months) compared to those not receiving either (~12–13 months), although the small sample size precluded statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.